Compare FuelCell Energy Inc (FCEL) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FuelCell Energy Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? FuelCell Energy Inc trades at $13.99 (market cap $1.24B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 6.1× FuelCell Energy Inc's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, FuelCell Energy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold FuelCell Energy Inc for 48 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| FCEL | SYRE | |
|---|---|---|
Market Cap | $1.24B | $7.52B |
Volume | 7,483,477 | 1,441,031 |
Sector | Industrials | Health |
52-Week High | $36.01 | $108.92 |
52-Week Low | $6.00 | $22.18 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | $818.79M | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FuelCell Energy (FCEL) trades at $14.16, down 13.5% over 24 hours, reflecting negative momentum amid ongoing operational losses. The stock exhibits a bearish technical signal, with key support at $14. Recent financials show revenue of $158.16M in 2025 but a net loss of $187.90M, with negative gross and net income margins. Analyst consensus is split evenly between Buy and Hold, with a $21.57 price target. Multiple law firms have announced securities class actions related to disclosures from June to September 2026, adding legal overhangs.
FCEL's outlook remains challenged by persistent unprofitability and cash burn, though analyst targets suggest potential upside from current levels. Key risks include the class action lawsuits, execution on scaling power agreements, and the company's ability to achieve positive cash flow. The stock presents a high-risk opportunity contingent on operational turnaround and resolution of legal issues.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
